CD4 and cancer: The combined CpG-ODN/LL-37 therapy, expression of interferon (IFN)-γ, inducing proliferation and activation of natural killer (NK) cells, but not CD4+ or CD8+ T cells, in the peritoneal cavity, ultimately increase the organism’s natural defenses against the cancer cells (Chuang et al. 2009).